Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Acute stroke and Neuroprotection

Department: Radcliffe Department of Medicine

Personal website: http://www.rdm.ox.ac.uk/principal-investigators/researcher/alastair-buchan

rof Alastair Buchan heads the Laboratory of Cerebral Ischaemia whose aim is to identify novel neuroprotective strategies that may be used for the treatment or prevention of an acute stroke. We conduct preclinical studies on putative neuroprotectants in models of stroke, while running human studies to identify potential targets for treatment strategies and markers for monitoring patients. We take a multimodal approach that involves aspects of cell and molecular biology, physiology, pharmacology, in vivo imaging, surgery and clinical medicine. Our interests currently lie in many exciting avenues of stroke research. We are identifying and targeting novel neuroprotective pathways following brain ischaemia such as the oxygen sensing mechanism, hypoxia inducible factor (HIF). We are also using proteomic and metabolomic techniques to identify new biomarkers for stroke. Other avenues of research include local and remote preconditioning as a neuroprotective strategy, and attempting to improve the efficacy of the only approved treatment for acute stroke, recombinant tissue plasminogen activator (rtPA).

Alastair M Buchan


Acute stroke and Neuroprotection

Prof Alastair Buchan heads the Laboratory of Cerebral Ischaemia whose aim is to identify novel neuroprotective strategies that may be used for the treatment or prevention of an acute stroke. We conduct preclinical studies on putative neuroprotectants in models of stroke, while running human studies to identify potential targets for treatment strategies and markers for monitoring patients. We take a multimodal approach that involves aspects of cell and molecular biology, physiology, pharmacology, in vivo imaging, surgery and clinical medicine. Our interests currently lie in many exciting avenues of stroke research. We are identifying and targeting novel neuroprotective pathways following brain ischaemia such as the oxygen sensing mechanism, hypoxia inducible factor (HIF). We are also using proteomic and metabolomic techniques to identify new biomarkers for stroke. Other avenues of research include local and remote preconditioning as a neuroprotective strategy, and attempting to improve the efficacy of the only approved treatment for acute stroke, recombinant tissue plasminogen activator (rtPA).